Drug-target interaction prediction: databases, web servers and computational models

Identification of drug-target interactions is an important process in drug discovery. Although high-throughput screening and other biological assays are becoming available, experimental methods for drug-target interaction identification remain to be extremely costly, time-consuming and challenging even nowadays. Therefore, various computational models have been developed to predict potential drug-target associations on a large scale. In this review, databases and web servers involved in drug-target identification and drug discovery are summarized. In addition, we mainly introduced some state-of-the-art computational models for drug-target interactions prediction, including network-based method, machine learning-based method and so on. Specially, for the machine learning-based method, much attention was paid to supervised and semi-supervised models, which have essential difference in the adoption of negative samples. Although significant improvements for drug-target interaction prediction have been obtained by many effective computational models, both network-based and machine learning-based methods have their disadvantages, respectively. Furthermore, we discuss the future directions of the network-based drug discovery and network approach for personalized drug discovery based on personalized medicine, genome sequencing, tumor clone-based network and cancer hallmark-based network. Finally, we discussed the new evaluation validation framework and the formulation of drug-target interactions prediction problem by more realistic regression formulation based on quantitative bioactivity data.

[1]  B. Stockwell Chemical genetics: ligand-based discovery of gene function , 2000, Nature Reviews Genetics.

[2]  P. Bork,et al.  A side effect resource to capture phenotypic effects of drugs , 2010, Molecular systems biology.

[3]  Hughes,et al.  Genomic technologies in drug discovery and development. , 1999, Drug discovery today.

[4]  Stuart L. Schreiber,et al.  Dissecting glucose signalling with diversity-oriented synthesis and small-molecule microarrays , 2002, Nature.

[5]  Hongyu Zhao,et al.  Drug target inference through pathway analysis of genomics data. , 2013, Advanced drug delivery reviews.

[6]  O. Franco,et al.  Proteomics applied to exercise physiology: A cutting‐edge technology , 2012, Journal of cellular physiology.

[7]  Xiaobo Zhou,et al.  Semi-supervised drug-protein interaction prediction from heterogeneous biological spaces , 2010, BMC Systems Biology.

[8]  Robert B. Russell,et al.  SuperTarget and Matador: resources for exploring drug-target relationships , 2007, Nucleic Acids Res..

[9]  Xing Chen,et al.  ASDCD: Antifungal Synergistic Drug Combination Database , 2014, PloS one.

[10]  Yoshihiro Yamanishi,et al.  Prediction of drug–target interaction networks from the integration of chemical and genomic spaces , 2008, ISMB.

[11]  Peter Imming,et al.  Drugs, their targets and the nature and number of drug targets , 2007, Nature Reviews Drug Discovery.

[12]  Yu Shyr,et al.  The prediction of interferon treatment effects based on time series microarray gene expression profiles , 2008, Journal of Translational Medicine.

[13]  L. Lai,et al.  Finding multiple target optimal intervention in disease-related molecular network , 2008, Molecular systems biology.

[14]  P. Hajduk,et al.  Navigating the kinome. , 2011, Nature chemical biology.

[15]  Evan Bolton,et al.  Database resources of the National Center for Biotechnology Information , 2017, Nucleic Acids Res..

[16]  Yoshihiro Yamanishi,et al.  DINIES: drug–target interaction network inference engine based on supervised analysis , 2014, Nucleic Acids Res..

[17]  Sarah L. Kinnings,et al.  Novel computational approaches to polypharmacology as a means to define responses to individual drugs. , 2012, Annual review of pharmacology and toxicology.

[18]  E. Marcotte,et al.  A flaw in the typical evaluation scheme for pair-input computational predictions , 2012, Nature Methods.

[19]  A. Hopkins,et al.  The druggable genome , 2002, Nature Reviews Drug Discovery.

[20]  Alexander E. Ivliev,et al.  Drug Target Prediction and Repositioning Using an Integrated Network-Based Approach , 2013, PloS one.

[21]  Xin Wen,et al.  BindingDB: a web-accessible database of experimentally determined protein–ligand binding affinities , 2006, Nucleic Acids Res..

[22]  Xiaomin Luo,et al.  PDTD: a web-accessible protein database for drug target identification , 2008, BMC Bioinformatics.

[23]  S. Haggarty,et al.  Multidimensional chemical genetic analysis of diversity-oriented synthesis-derived deacetylase inhibitors using cell-based assays. , 2003, Chemistry & biology.

[24]  A. Hopkins Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.

[25]  Hailin Chen,et al.  A Semi-Supervised Method for Drug-Target Interaction Prediction with Consistency in Networks , 2013, PloS one.

[26]  M S Waterman,et al.  Identification of common molecular subsequences. , 1981, Journal of molecular biology.

[27]  Tapio Pahikkala,et al.  Toward more realistic drug^target interaction predictions , 2014 .

[28]  Edwin Wang,et al.  Cancer systems biology in the genome sequencing era: part 1, dissecting and modeling of tumor clones and their networks. , 2013, Seminars in cancer biology.

[29]  Fang Liu,et al.  Functional association between influenza A (H1N1) virus and human. , 2009, Biochemical and biophysical research communications.

[30]  Yoshihiro Yamanishi,et al.  Supervised prediction of drug–target interactions using bipartite local models , 2009, Bioinform..

[31]  Hua Yu,et al.  A Systematic Prediction of Multiple Drug-Target Interactions from Chemical, Genomic, and Pharmacological Data , 2012, PloS one.

[32]  Edwin Wang,et al.  Cancer systems biology in the genome sequencing era: part 2, evolutionary dynamics of tumor clonal networks and drug resistance. , 2013, Seminars in cancer biology.

[33]  T. Ashburn,et al.  Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.

[34]  Mathias Dunkel,et al.  SuperPred: update on drug classification and target prediction , 2014, Nucleic Acids Res..

[35]  Bryan L Roth,et al.  Strategies to discover unexpected targets for drugs active at G protein-coupled receptors. , 2011, Annual review of pharmacology and toxicology.

[36]  P. Bork,et al.  Drug discovery in the age of systems biology: the rise of computational approaches for data integration. , 2012, Current opinion in biotechnology.

[37]  Hao Ding,et al.  Similarity-based machine learning methods for predicting drug-target interactions: a brief review , 2014, Briefings Bioinform..

[38]  Xin Chen,et al.  DCDB: Drug combination database , 2010, Bioinform..

[39]  John P. Overington,et al.  How many drug targets are there? , 2006, Nature Reviews Drug Discovery.

[40]  Jennifer Venhorst,et al.  Target-drug interactions: first principles and their application to drug discovery. , 2012, Drug discovery today.

[41]  C. Dobson Chemical space and biology , 2004, Nature.

[42]  J. Drews Drug discovery: a historical perspective. , 2000, Science.

[43]  J. Lamerdin,et al.  Identifying off-target effects and hidden phenotypes of drugs in human cells , 2006, Nature chemical biology.

[44]  Michael J. Keiser,et al.  Predicting new molecular targets for known drugs , 2009, Nature.

[45]  Chang Liu,et al.  Predicting Drug–Target Interactions Using Probabilistic Matrix Factorization , 2013, J. Chem. Inf. Model..

[46]  Philip E. Bourne,et al.  SuperTarget goes quantitative: update on drug–target interactions , 2011, Nucleic Acids Res..

[47]  Bruce Randall Donald,et al.  Algorithms in Structural Molecular Biology , 2011 .

[48]  D. Bojanic,et al.  Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development. , 2005, Drug discovery today.

[49]  D. L. Taylor,et al.  Advances in high content screening for drug discovery. , 2003, Assay and drug development technologies.

[50]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[51]  Charles C. Persinger,et al.  How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.

[52]  S. Frantz Drug discovery: Playing dirty , 2005, Nature.

[53]  J. Lehár,et al.  Multi-target therapeutics: when the whole is greater than the sum of the parts. , 2007, Drug discovery today.

[54]  Bissan Al-Lazikani,et al.  canSAR: an integrated cancer public translational research and drug discovery resource , 2011, Nucleic Acids Res..

[55]  Yuhao Wang,et al.  Predicting drug-target interactions using restricted Boltzmann machines , 2013, Bioinform..

[56]  J. Gies,et al.  Drugs and their molecular targets: an updated overview , 2008, Fundamental & clinical pharmacology.

[57]  M. Kanehisa,et al.  Development of a chemical structure comparison method for integrated analysis of chemical and genomic information in the metabolic pathways. , 2003, Journal of the American Chemical Society.

[58]  Chee Keong Kwoh,et al.  Drug-target interaction prediction by learning from local information and neighbors , 2013, Bioinform..

[59]  Dong-Sheng Cao,et al.  Computational Prediction of DrugTarget Interactions Using Chemical, Biological, and Network Features , 2014, Molecular informatics.

[60]  Hui Yu,et al.  Predicting Drug-Target Interactions via Within-Score and Between-Score , 2015, BioMed research international.

[61]  Damian Szklarczyk,et al.  STITCH 4: integration of protein–chemical interactions with user data , 2013, Nucleic Acids Res..

[62]  Aurélien Grosdidier,et al.  SwissTargetPrediction: a web server for target prediction of bioactive small molecules , 2014, Nucleic Acids Res..

[63]  S. Giordano,et al.  From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. , 2008, Current medicinal chemistry.

[64]  Joanna L. Sharman,et al.  The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands , 2013, Nucleic Acids Res..

[65]  Ryan G. Coleman,et al.  ZINC: A Free Tool to Discover Chemistry for Biology , 2012, J. Chem. Inf. Model..

[66]  David S. Goodsell,et al.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..

[67]  Xing Chen,et al.  Drug-target interaction prediction by random walk on the heterogeneous network. , 2012, Molecular bioSystems.

[68]  C. Yap,et al.  Progress and problems in the exploration of therapeutic targets. , 2006, Drug discovery today.

[69]  E. Wang,et al.  Predictive genomics: a cancer hallmark network framework for predicting tumor clinical phenotypes using genome sequencing data. , 2014, Seminars in cancer biology.

[70]  Mindy I. Davis,et al.  Comprehensive analysis of kinase inhibitor selectivity , 2011, Nature Biotechnology.

[71]  James B Golden,et al.  Prioritizing the human genome: knowledge management for drug discovery. , 2003, Current opinion in drug discovery & development.

[72]  Kiyoko F. Aoki-Kinoshita,et al.  From genomics to chemical genomics: new developments in KEGG , 2005, Nucleic Acids Res..

[73]  Rahul Kumar,et al.  CancerDR: Cancer Drug Resistance Database , 2013, Scientific Reports.

[74]  Yoshihiro Yamanishi,et al.  Drug-target interaction prediction from chemical, genomic and pharmacological data in an integrated framework , 2010, Bioinform..

[75]  Daniel R. Caffrey,et al.  Structure-based maximal affinity model predicts small-molecule druggability , 2007, Nature Biotechnology.

[76]  Chuang Liu,et al.  Prediction of Drug-Target Interactions and Drug Repositioning via Network-Based Inference , 2012, PLoS Comput. Biol..

[77]  M. Dickson,et al.  Key factors in the rising cost of new drug discovery and development , 2004, Nature Reviews Drug Discovery.

[78]  Feng Xu,et al.  Therapeutic target database update 2014: a resource for targeted therapeutics , 2013, Nucleic Acids Res..

[79]  Xing Chen,et al.  Novel human lncRNA-disease association inference based on lncRNA expression profiles , 2013, Bioinform..

[80]  Wei Liu,et al.  Screening drug target proteins based on sequence information , 2014, J. Biomed. Informatics.

[81]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[82]  David S. Wishart,et al.  DrugBank 4.0: shedding new light on drug metabolism , 2013, Nucleic Acids Res..

[83]  P. Bork,et al.  Drug Target Identification Using Side-Effect Similarity , 2008, Science.

[84]  Martin Serrano,et al.  Nucleic Acids Research Advance Access published October 18, 2007 ChemBank: a small-molecule screening and , 2007 .

[85]  David S. Roos,et al.  TDR Targets: a chemogenomics resource for neglected diseases , 2011, Nucleic Acids Res..

[86]  Lei Chen,et al.  A two-step similarity-based method for prediction of drug's target group. , 2013, Protein and peptide letters.